Bio Gene Technology Stock Working Capital
| BGT Stock | 0.04 0 2.44% |
Bio Gene Technology fundamentals help investors to digest information that contributes to Bio Gene's financial success or failures. It also enables traders to predict the movement of Bio Stock. The fundamental analysis module provides a way to measure Bio Gene's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bio Gene stock.
Net Working Capital is likely to gain to about 4.1 M in 2024, despite the fact that Change In Working Capital is likely to grow to (364.3 K). Bio | Working Capital |
Bio Gene Technology Company Working Capital Analysis
Bio Gene's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Bio Gene Working Capital | 2.59 M |
Most of Bio Gene's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bio Gene Technology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Bio Net Invested Capital
Net Invested Capital |
|
In accordance with the company's disclosures, Bio Gene Technology has a Working Capital of 2.59 M. This is 99.39% lower than that of the Chemicals sector and 99.52% lower than that of the Materials industry. The working capital for all Australia stocks is 99.82% higher than that of the company.
Bio Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bio Gene's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bio Gene could also be used in its relative valuation, which is a method of valuing Bio Gene by comparing valuation metrics of similar companies.Bio Gene is currently under evaluation in working capital category among its peers.
Bio Fundamentals
| Return On Equity | -0.8 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 6.05 M | |||
| Shares Outstanding | 201.36 M | |||
| Shares Owned By Insiders | 43.33 % | |||
| Price To Book | 2.89 X | |||
| Price To Sales | 450.65 X | |||
| Revenue | 18.32 K | |||
| Gross Profit | 222.1 K | |||
| EBITDA | (2.97 M) | |||
| Net Income | (2.41 M) | |||
| Total Debt | 368.45 K | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (2.75 M) | |||
| Earnings Per Share | (0.01) X | |||
| Target Price | 0.37 | |||
| Beta | 0.71 | |||
| Market Capitalization | 8.26 M | |||
| Total Asset | 3.16 M | |||
| Retained Earnings | (19.64 M) | |||
| Working Capital | 2.59 M | |||
| Net Asset | 3.16 M |
About Bio Gene Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bio Gene Technology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bio Gene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bio Gene Technology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bio Stock Analysis
When running Bio Gene's price analysis, check to measure Bio Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Gene is operating at the current time. Most of Bio Gene's value examination focuses on studying past and present price action to predict the probability of Bio Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Gene's price. Additionally, you may evaluate how the addition of Bio Gene to your portfolios can decrease your overall portfolio volatility.